Researchers at Bristol Myers Squibb (BMS) are leading the charge in advancing the understanding of diffuse large B-cell lymphoma (DLBCL), leveraging cutting-edge technology to uncover critical insights. Using high-resolution imaging, the BMS research team is pioneering new ways to analyze the intricate spatial relationships within the tumor microenvironment (TME)—areas where traditional methods have fallen short.

The team has revealed distinct cellular neighborhoods within the TME, highlighting the roles of immune cells. One of their key discoveries is the correlation between double-positive macrophages and poorer clinical outcomes, a finding that could inform future therapeutic approaches.

They have also uncovered novel mechanisms of immune evasion. Aided by high-resolution imaging, the team observed the physical separation of tumor cells from T helper cells. They also noted clustering around immune-suppressive cells, providing new insights into how tumors evade immune responses. These groundbreaking findings are laying the foundation for targeted immune-oncology therapies that could improve patient outcomes.

To dive deeper into how DLBCL research is being reshaped, read the full case study here.